Malaisia - inglise - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - zoledronic acid monohydrate -

Malaisia - inglise - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - irinotecan hydrochloride trihydrate -

Malaisia - inglise - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - docetaxel -

Malaisia - inglise - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - pemetrexed disodium 2.5 hydrate -

Malaisia - inglise - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - pemetrexed disodium 2.5 hydrate -

Iisrael - inglise - Ministry of Health

a.l. medi-market ltd. - irinotecan hydrochloride trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg / 1 ml - irinotecan - irinotecan hcl seacross is indicated for the treatment of patients with metastatic colorectal cancer: in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer. irinotecan in combination with leucovorin, oxaliplatin and 5-fluorouracil for the first-line treatment of patients with metastatic pancreatic adenocarcinoma

Iisrael - inglise - Ministry of Health

a.l. medi-market ltd. - docetaxel anhydrous - concentrate for solution for infusion - docetaxel anhydrous 20 mg / 1 ml - docetaxel - breast cancer : docetaxel seacross 20 mg/ml in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer .docetaxel seacross 20 mg/ml in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition .docetaxel seacross 20 mg/ml monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent .docetaxel seacross 20 mg/ml in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease .docetaxel seacross 20 mg/ml in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline. doxorubicin and cyclophosphamide followed by docetaxel seacross 20 mg/ml in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with her2 over-expressing, node-positive or high risk node-negative, breast cancer .docetaxel seacross 20 mg/ml in combination with trastuzumab, and carboplatin (tch) is indicated for the adjuvant treatment of patients with her2 over-expressing, node-positive or high risk node-negative, breast cancer.non-small cell lung cancer : docetaxel seacross 20 mg/ml is indicated for the treatment of patients with advanced non-small cell lung carcinoma. ovarian cancer : docetaxel seacross 20 mg/ml is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy .prostate cancer : docetaxel seacross 20 mg/ml in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer . esophageal cancer : docetaxel seacross 20 mg/ml for the treatment of esophageal cancer.gastric cancer : docetaxel seacross 20 mg/ml for the treatment of advanced gastric cancer.head and neck (scchn): docetaxel seacross 20 mg/ml as monotherapy in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.docetaxel seacross 20 mg/ml in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

Malaisia - inglise - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - zoledronic acid monohydrate -

Malaisia - inglise - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

first pharmaceutical sdn. bhd. - palonosetron (as hydrochloride) -